Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Literature assessing the impact of palliative care (PC) consultation on aggressive care at the end of life (EOL) within a comprehensive integrated PC program is limited. We retrospectively reviewed patients with advanced cancer who received oncological care at a Canadian tertiary center, died between April 2013 and March 2014, and had access to PC consultation in all healthcare settings. Administrative databases were linked, and medical records reviewed. Composite score for aggressive EOL care was calculated, assigning a point for each of the following: ≥2 emergency room visits, ≥2 hospitalizations, hospitalization >14 days, ICU admission, and chemotherapy administration in the last 30 days of life, and hospital death. Multivariable logistic regression was adjusted for age, sex, income, cancer type and PC consultation for ≥1 aggressive EOL care indicator. Of 1414 eligible patients, 1111 (78.6%) received PC consultation. In multivariable analysis, PC consultation was independently associated with lower odds of ≥1 aggressive EOL care indicator (OR 0.49, 95% CI 0.38−0.65, p < 0.001). PC consultation >3 versus ≤3 months before death had a greater effect on lower aggressive EOL care (mean composite score 0.59 versus 0.88, p < 0.001). We add evidence that PC consultation is associated with less aggressive care at the EOL for patients with advanced cancer.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858595PMC
http://dx.doi.org/10.3390/curroncol30010068DOI Listing

Publication Analysis

Top Keywords

aggressive eol
16
eol care
16
patients advanced
12
advanced cancer
12
care
10
comprehensive integrated
8
palliative care
8
aggressive care
8
composite score
8
≥1 aggressive
8

Similar Publications

Systemic anticancer therapy during end of life in head and neck squamous cell carcinoma patients. A retrospective single center study.

J Cancer Res Clin Oncol

August 2025

Department of Head and Neck Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano, Italy.

Purpose: Systemic anticancer treatments (SACTs) are used in advanced cancer stages to control disease and improve survival. However, their use at the end of life (Eol) can lead to side effects. This study aims to assess the clinical implications of SACTs near the Eol in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

View Article and Find Full Text PDF

Purpose: Metastatic breast cancer (MBC) is incurable, despite therapeutic advances, especially in hormone receptor positive (HR+) and human epidermal growth factor-2 negative (HER2-) disease. Specialist palliative care (SPC) is recommended to alleviate distress and reduce overly aggressive end-of-life (EoL) care. This study determined rates of SPC, hospice utilization, and aggressive EoL care in patients with HR+/HER2- MBC.

View Article and Find Full Text PDF

Background: Neuroendocrine tumors (NETs) are a diverse group of malignancies with increasing incidence. Early diagnosis is challenging-most patients present with advanced disease, which is associated with a heavy symptom burden. The role of palliative care in the management of NETs is critical but inadequately explored.

View Article and Find Full Text PDF

Background: Aggressive end-of-life (EOL) care, such as systemic anticancer therapy (SACT) for advanced cancer patients, represents a potential indicator of low-quality care that may deviate from the primary palliative objective of treatment.

Methods: A retrospective study analyzed consecutive patients with advanced cancers treated at a tertiary oncology center in Israel from January 2019 to December 2022. Demographic and clinical data were examined, with a focus on intravenous (IV) oncologic treatment administration rates at 30 and 90 days before death.

View Article and Find Full Text PDF

Background: Patients with incurable cancer deserve quality end-of-life (EOL) care. Despite established EOL quality metrics, many patients receive aggressive EOL care with limited goals of care (GOC) documentation. Concurrently, clinical trials are critical for advancing cancer care.

View Article and Find Full Text PDF